About

Liang Schweizer is the Founder, Board Chair and Chief Executive Officer of HiFiBiO Therapeutics. She has over 30 years of research and industry experience with numerous publications and global keynote presentations. She is the co-inventor of 12 immuno-modulatory therapeutic antibodies with over 50 patent publications. She also has contributed to 4 marketed drugs and over 30 clinical candidates. In recognition of her leadership, she has been awarded the EY Entrepreneur of the Year New England in 2024 and HiFiBiO Therapeutics recognized as a Fierce 15 Biotech in 2023.

Previously, Liang co-founded Harbour Biomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, she was a director at Bristol-Myers Squibb Company.

Liang received a B.S. from the University of Science and Technology of China (USTC) and an M.S. in Microbial Engineering and Chemical Engineering from the University of Minnesota. She earned her Ph.D. in Molecular Biology from the University in Zurich. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC).

Percy Carter is the Chief Scientific Officer of Blueprint Medicines (NASDAQ: BPMC). He has over 20 years of R&D experience in global pharmaceutical companies. He is also an inventor or co-inventor on more than 28 U.S. patents and has authored or co-authored numerous peer-reviewed publications.

Prior to joining Blueprint Medicines, he served as Chief Scientific Officer at FibroGen, Inc. He previously served as Global Head of Discovery Sciences at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, where he led more than 700 employees comprising several key research and discovery functions and drove the synthetic discovery strategy in collaboration with partners across various therapeutic areas. From August 2001 to May 2019, Percy held roles of increasing responsibility in drug discovery, covering all therapeutic areas, drug platforms and stages of discovery at Bristol-Myers Squibb (BMS), including serving as Senior Vice President and Head of Discovery. Prior to his experience at BMS, he was Senior Research Scientist in Chemical and Physical Sciences at DuPont Pharmaceuticals, until it was acquired by BMS in 2001.

 Percy received an A.B. in Chemistry from Dartmouth College and a Ph.D. in Organic Chemistry from Harvard University. In addition, he received an MBA from Massachusetts Institute of Technology.

Carl L. Liederman is the Founder and CEO of LIEDERSHIP. He has over 30 years of experience in corporate strategy and international corporate governance.

He has led deals in over 90 countries across a wide variety of activities, including cross-border M&A, joint ventures, strategic alliances, capital markets, private equity, venture capital, and board governance.  He has been involved across major sectors including finance, manufacturing, FMCG, TMT, and health care (pharma, biotech, and medtech). Carl currently serves on the board of ShareAction. He has previously held board positions at PreComb Therapeutics, Converge, Right to Play International, and MIX.

Carl is a member of the bars of New York and Washington, DC.  He received his J.D. from Yale Law School and his B.A. from Pomona College.  He is fluent in French and conversant in Italian, Spanish and Greek.

HyoJeong Kim is the Healthcare Team Manager for Mirae Asset Capital, managing investments in the healthcare industry. Her portfolio includes notable companies such as inSilico Medicine, Sonoma Biotherapeutics, and Akili Interactive.

Prior to Mirae Asset, HyoJeong was a Venture Capitalist at SpringCamp focusing on early-stage startups. Before SpringCamp, HyoJeong was Marketing Manager at Janssen Korea. HyoJeong holds a B.A. in Pharmacy from Seoul National University.

Cheryle Cui is a Partner at Nest.Bio Ventures and CEO of Bota.

She was a former Venture Partner at VentureHealth, a Silicon Valley-based healthcare fund, where she coordinated portfolio companies’ growth strategy in the Asia Pacific. Cheryl previously co-founded a mobile health company that facilitates the care of Alzheimer’s patients, which was successfully acquired in 2012 and led to her selection as one of Canada’s Next 36. She currently serves as a Board Member of Rootpath and HiFiBio Therapeutics.

Cheryl earned her joint PhD degree in Medical Engineering and Medical Physics from MIT and Harvard Medical School and her B.A.Sc. in Engineering Science and Biomedical Engineer from the University of Toronto.

Lynn Yang is a Partner at HongShan, focusing on the healthcare sector, where she has led investments in numerous renowned healthcare enterprises.

Prior to joining HongShan in 2015, she worked at Legend Capital healthcare team. Previously, Lynn Yang served as a Business Development Manager and Product Manager at major multinational companies such as Johnson & Johnson and GE Healthcare.

She holds an MBA from Duke University in the United States and a master’s degree in clinical medicine from Tongji Medical College of Huazhong University of Science and Technology.

Zixuan is the Vice President at IDG Capital. He focuses on early-stage biotech investments, new modality, and disruptive biotechnologies.

Before becoming the Vice President, Zixuan served as Associate at IDG Capital in Beijing, dealing sourcing, research, and led a few investments in the biotech sector. 

Zixuan received his Ph.D. in Philosophy, Neuroscience, Dermatology, and Biochemistry from the Johns Hopkins University School of Medicine, and Bachelor of Science in Biology, Bachelor of Arts in International Politics from Peking University.